GlassScriptPhysician profile
Henry C Okere
NPI 1366455248
$16,908.59
in general payments reported to CMS, 2019-2025
42 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,647 · 2020: $2,215 · 2021: $2,346 · 2022: $2,842 · 2023: $2,679 · 2024: $2,150 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,488 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,487.99 |
| Education | $369.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,889.18 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,715.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,409.48 | 2019-2025 | Xifaxan, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,346.86 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,342.93 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $1,301.33 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,016.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $962.63 | 2019-2025 | Freestyle Libre |
| Pfizer INC. | $693.04 | 2019-2025 | |
| Astellas Pharma US INC | $689.44 | 2019-2025 | Veozah |
| Amgen INC. | $686.50 | 2019-2024 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $445.91 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $426.45 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $328.20 | 2019-2024 | |
| Horizon Therapeutics Plc | $325.53 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Okere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.